Although bortezomib is not a specific inhibitor of Skp2, it protected p27 from Skp2-mediated ubiquitination by inhibiting the proteasome function, resulting in suppressed colony formation ability of chronic myelogenous leukemia cells and increased apoptosis rate (12). Here, SKP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.